Damora Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 19, 2025
DMRA$24.07+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share amounts)
| Mezzanine Equity · Stockholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · AdditionalPaid-In · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance at December 31, 2022 | — | $— | 1,026,097 | $— | $279,733 | $(217,736) | $(244) | $61,753 |
| Stock-based compensation expense | — | — | — | — | 5,427 | — | — | 5,427 |
| Issuance of common stock; net of issuance costs of $0.2 million | — | — | 58,412 | — | 2,876 | — | — | 2,876 |
| Other comprehensive income, net | — | — | — | — | — | — | 624 | 624 |
| Net loss | — | — | — | — | — | (38,349) | — | (38,349) |
| Balance at December 31, 2023 | — | — | 1,084,509 | — | 288,036 | (256,085) | 380 | 32,331 |
| Stock-based compensation expense | — | — | — | — | 3,239 | — | — | 3,239 |
| Issuance of common stock in connection with vesting of restricted stock units | — | — | 6,828 | — | 93 | — | — | 93 |
| Issuance of preferred and common stock in connection with an Asset Purchase Agreement | 161 | 1,360 | 62,594 | — | 530 | — | — | 1,890 |
| Round-up shares from the 1-for-25 reverse split effective August 29, 2024 | — | — | 163,058 | — | — | — | — | — |
| Other comprehensive loss, net | — | — | — | — | — | — | (283) | (283) |
| Net loss | — | — | — | — | — | (21,439) | — | (21,439) |
| Balance at December 31, 2024 | 161 | $1,360 | 1,316,989 | $— | $291,898 | $(277,524) | $97 | $15,831 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.